COSIMO Cancer Associated Thrombosis - Patient Reported Outcomes With Rivaroxaban. A Non-interventional Study on Patients Changing to Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer.
Phase of Trial: Phase IV
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Pulmonary embolism; Venous thromboembolism
- Focus Therapeutic Use
- Acronyms COSIMO
- Sponsors Bayer
- 10 Nov 2016 Status changed from not yet recruiting to recruiting.
- 12 Oct 2016 Planned initiation date changed from 1 Sep 2016 to 1 Oct 2016.
- 14 Jul 2016 Planned initiation date changed from 1 Jul 2016 to 1 Sep 2016.